Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neighbourly Pharmacy Inc T.NBLY

Neighbourly Pharmacy Inc. is a Canada-based company that operates a network of community pharmacies. The Company is an owner and operator of retail pharmacies located throughout Canada under banners such as IDA/Guardian, Pharmachoice, Pharmasave and Remedy’s RX. The Company, through its subsidiaries, owns and operates a network of retail pharmacies known as Rubicon Pharmacies (Rubicon or Rubicon Pharmacies. The Company owns and operates approximately 287 locations across seven provinces and one territory, a coast-to-coast footprint that provides scale and diversification. The Company’s pharmacies provide accessible healthcare with a personal touch. The Company also owns British Columbia-based pharmacies.


TSX:NBLY - Post by User

Post by incomedreamer11on Aug 02, 2022 9:13am
145 Views
Post# 34865224

TD comments on last result

TD comments on last resultNeighbourly Pharmacy Inc. (NBLY-T) C$23.21 Q1/23

First Look: Temporarily Higher Costs Pressured Margin Derek J. Lessard Cheryl Zhang, (Associate)

Event Neighbourly reported Q1/23 adj. EBITDA of $11.3mm vs. $10.1mm LY (+11% y/ y), below consensus of $12.3mm (range: $11.7mm to $14.0mm).

Impact: SLIGHTLY NEGATIVE


While the Q1/23 results came in slightly softer than expected, we expect the pressures, namely the lag in in-person physician visit recovery and the pharmacist shortages, to diminish over the next 12 months. Specifically, the reduced funding for virtual care in Ontario starting in September, as well as the accelerated immigration programs (which should bring in international pharmacy graduates), should encourage in-person clinical activities and increase the supply of pharmacists, in our view. We believe the initial highlights of the quarter include
  Revenue: Up 34% y/y to $114.4mm (cons: $115.8mm), driven by the addition of 43 pharmacies y/y (accounts for 96% of the growth) and SSSG of 1.8%. Samestore prescription growth was only 0.4%, impacted by a higher proportion of clinical locations and the continued softness in in-person physician visits and new prescriptions.
Adj. EBITDA: Margin decreased ~200bps y/y, mostly due to:
1) ~70bps decline in gross margin tied to higher proportion of clinical locations (40% vs. 32% LY), which typically dispense a higher mix of lower percentage-margin branded drugs;
2) incremental labour cost as a result of longer-than-usual time to fill pharmacist vacancies;
3) impact of new scripts on revenue.

We expect margins to materially improve starting in Q2, driven by the Rubicon acquisition and better mix. The conference call is at 8:30 am and we expect the focus to centre on the cost environment and any developments on pharmacist vacancies.
<< Previous
Bullboard Posts
Next >>